中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies

文献类型：期刊论文

作者Liang, Xuewu1; Cao, YiChun2; Li, Chunpu1; Yu, Haolan3; Yang, Chenghua3; Liu, Hong1
刊名MEDICINAL RESEARCH REVIEWS
出版日期2021-03-25
页码35
关键词DLBCL MALT lymphoma MALT1 MALT1 inhibitors NF‐ κ B pathway
ISSN号0198-6325
DOI10.1002/med.21799
通讯作者Yang, Chenghua(chenghua-yang@qq.com) ; Liu, Hong(hliu@simm.ac.cn)
英文摘要Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key adaptor protein that regulates the NF-kappa B pathway, in which MALT1 functions as a scaffold protein and protease to trigger downstream signals. The abnormal expression of MALT1 is closely associated with lymphomagenesis and other diseases, including solid tumors and autoimmune diseases. MALT1 is the only protease in the underlying pathogenesis of these diseases, and its proteolytic activity can be pharmacologically regulated. Therefore, MALT1 is a potential and promising target for anti-lymphoma and other MALT1-related disease treatments. Currently, the development of MALT1 inhibitors is still in its early stages. This review presents an overview of MALT1, particularly its X-ray structures and biological functions, and elaborates on the pathogenesis of diseases associated with its dysregulation. We then summarize previously reported MALT1 inhibitors, focusing on their molecular structure, biological activity, structure-activity relationship, and limitations. Finally, we propose future research directions to accelerate the discovery of novel MALT1 inhibitors with clinical applications. Overall, this review provides a comprehensive and systematic overview of MALT1-related research advances and serves as a theoretical basis for drug discovery and research.
资助项目National Natural Science Foundation of China[21907102] ; National Natural Science Foundation of China[21632008] ; National Natural Science Foundation of China[91229204] ; National Natural Science Foundation of China[81473245] ; National Natural Science Foundation of China[81772695]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000632366400001
出版者WILEY
源URL[http://119.78.100.183/handle/2S10ELR8/295391]  
专题新药研究国家重点实验室
通讯作者Yang, Chenghua; Liu, Hong
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
2.Fudan Univ, Sch Pharm, Shanghai, Peoples R China
3.Second Mil Med Univ, Changhai Hosp, Dept Urol, 168 Chang Hai Rd, Shanghai 200433, Peoples R China
推荐引用方式
GB/T 7714		 Liang, Xuewu,Cao, YiChun,Li, Chunpu,et al. MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies[J]. MEDICINAL RESEARCH REVIEWS,2021:35.
APA Liang, Xuewu,Cao, YiChun,Li, Chunpu,Yu, Haolan,Yang, Chenghua,&Liu, Hong.(2021).MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies.MEDICINAL RESEARCH REVIEWS,35.
MLA Liang, Xuewu,et al."MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies".MEDICINAL RESEARCH REVIEWS (2021):35.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。